Rubella - Pipeline Review, H1 2014 - WECT TV6-WECT.com:News, weather & sports Wilmington, NC

Rubella - Pipeline Review, H1 2014

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE ReportBuyer

LONDON, June 12, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:
Rubella - Pipeline Review, H1 2014

http://www.reportbuyer.com/pharma_healthcare/diseases/rubella_pipeline_review_h1_2013.html

Rubella - Pipeline Review, H1 2014

Summary

Global Markets Direct's, 'Rubella - Pipeline Review, H1 2014', provides an overview of the Rubella's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Rubella, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rubella and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Rubella
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Rubella and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Rubella products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Rubella pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Rubella
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Rubella pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Introduction 5
Global Markets Direct Report Coverage 5
Rubella Overview 6
Therapeutics Development 7
Pipeline Products for Rubella - Overview 7
Pipeline Products for Rubella - Comparative Analysis 8
Rubella - Therapeutics under Development by Companies 9
Rubella - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Rubella - Products under Development by Companies 14
Rubella - Companies Involved in Therapeutics Development 15
GlaxoSmithKline plc 15
Zydus Cadila Healthcare Limited 16
Cadila Pharmaceuticals Ltd. 17
Sinovac Biotech Ltd. 18
Beijing Tiantan Biological Products Co., Ltd. 19
Universal Stabilization Technologies, Inc. 20
Rubella - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Combination Products 22
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
measles, mumps and rubella vaccine (live) - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Vaccine for Live Measles, Mumps and Rubella - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Live Attenuated Vaccine For Rubella - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Measles and Rubella Vaccine - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Rubella Vaccine - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
MMR + Varicella Vaccine - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Vaccine for Measles and Rubella - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Rubella - Recent Pipeline Updates 34
Rubella - Dormant Projects 35
Rubella - Product Development Milestones 36
Featured News & Press Releases 36
Mar 15, 2012: CHMP Adopts Positive Opinion Recommending Variation To Terms Of Marketing Authorization For Proquad 36
Appendix 37
Methodology 37
Coverage 37
Secondary Research 37
Primary Research 37
Expert Panel Validation 37
Contact Us 38
Disclaimer 38

List of Tables

Number of Products under Development for Rubella, H1 2014 7
Number of Products under Development for Rubella - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 10
Comparative Analysis by Late Stage Development, H1 2014 11
Comparative Analysis by Clinical Stage Development, H1 2014 12
Comparative Analysis by Early Stage Development, H1 2014 13
Products under Development by Companies, H1 2014 14
Rubella - Pipeline by GlaxoSmithKline plc, H1 2014 15
Rubella - Pipeline by Zydus Cadila Healthcare Limited, H1 2014 16
Rubella - Pipeline by Cadila Pharmaceuticals Ltd., H1 2014 17
Rubella - Pipeline by Sinovac Biotech Ltd., H1 2014 18
Rubella - Pipeline by Beijing Tiantan Biological Products Co., Ltd., H1 2014 19
Rubella - Pipeline by Universal Stabilization Technologies, Inc., H1 2014 20
Assessment by Monotherapy Products, H1 2014 21
Assessment by Combination Products, H1 2014 22
Number of Products by Stage and Route of Administration, H1 2014 24
Number of Products by Stage and Molecule Type, H1 2014 26
Rubella Therapeutics - Recent Pipeline Updates, H1 2014 34
Rubella - Dormant Projects, H1 2014 35

List of Figures


Number of Products under Development for Rubella, H1 2014 7
Number of Products under Development for Rubella - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Comparative Analysis by Clinical Stage Development, H1 2014 12
Comparative Analysis by Early Stage Products, H1 2014 13
Assessment by Monotherapy Products, H1 2014 21
Number of Products by Top 10 Route of Administration, H1 2014 23
Number of Products by Stage and Top 10 Route of Administration, H1 2014 24
Number of Products by Top 10 Molecule Type, H1 2014 25
Number of Products by Stage and Top 10 Molecule Type, H1 2014 26

Companies Mentioned
GlaxoSmithKline plc
Zydus Cadila Healthcare Limited
Cadila Pharmaceuticals Ltd.
Sinovac Biotech Ltd.
Beijing Tiantan Biological Products Co., Ltd.
Universal Stabilization Technologies, Inc.

Read the full report:
Rubella - Pipeline Review, H1 2014

http://www.reportbuyer.com/pharma_healthcare/diseases/rubella_pipeline_review_h1_2013.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow